Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: results of the CAMI-GUIDE study.

Biasucci LM, Bellocci F, Landolina M, Rordorf R, Vado A, Menardi E, Giubilato G, Orazi S, Sassara M, Castro A, Massa R, Kheir A, Zaccone G, Klersy C, Accardi F, Crea F.

Eur Heart J. 2012 Jun;33(11):1344-50. doi: 10.1093/eurheartj/ehr487. Epub 2012 Jan 26.

2.

Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.

Bellocci F, Biasucci LM, Gensini GF, Padeletti L, Raviele A, Santini M, Giubilato G, Landolina M, Biondi-Zoccai G, Raciti G, Sassara M, Castro A, Kheir A, Crea F.

J Cardiovasc Med (Hagerstown). 2007 Apr;8(4):293-9.

PMID:
17413310
3.

Defining potential to benefit from implantable cardioverter defibrillator therapy: the role of biomarkers.

Scott PA, Townsend PA, Ng LL, Zeb M, Harris S, Roderick PJ, Curzen NP, Morgan JM.

Europace. 2011 Oct;13(10):1419-27. doi: 10.1093/europace/eur147. Epub 2011 Jul 21.

5.

Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy: impact on primary prevention of sudden cardiac death.

Paranskaya L, Akin I, Chatterjee T, Ritz A, Paranski P, Rehders T, Ince H, Schneider H, Nienaber CA, Bänsch D.

Herzschrittmacherther Elektrophysiol. 2011 Dec;22(4):243-8. doi: 10.1007/s00399-011-0160-z.

PMID:
22124800
6.

New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.

Klein H, Auricchio A, Reek S, Geller C.

Am J Cardiol. 1999 Mar 11;83(5B):91D-97D. Review.

PMID:
10089848
7.

Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.

Francia P, Adduci C, Semprini L, Borro M, Ricotta A, Sensini I, Santini D, Caprinozzi M, Balla C, Simmaco M, Volpe M.

J Cardiovasc Electrophysiol. 2014 Jun;25(6):609-16. doi: 10.1111/jce.12364. Epub 2014 Jan 30.

PMID:
24400815
8.

Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators.

Manios EG, Kallergis EM, Kanoupakis EM, Mavrakis HE, Kambouraki DC, Arfanakis DA, Vardas PE.

Chest. 2005 Oct;128(4):2604-10.

PMID:
16236931
9.

Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction.

Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, Aliot E, Zannad F.

Europace. 2007 Sep;9(9):724-9. Epub 2007 May 24.

10.

Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.

Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, Varanasi S, Prakash A, Delfaut P, Lewis CB.

Am J Cardiol. 1997 Sep 11;80(5B):3F-9F.

PMID:
9291444
11.

Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design.

Raviele A, Bongiorni MG, Brignole M, Cappato R, Capucci A, Gaita F, Mangiameli S, Montenero A, Pedretti R, Salerno J, Sermasi S.

Am J Cardiol. 1999 Mar 11;83(5B):104D-111D.

PMID:
10089851
12.

Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure.

Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautière K, Collet JP, Beygui F, Hennache B, Ennezat PV, Juthier F, Richard F, Dallongeville J, Hillaert MA, Doevendans PA, Jude B, Bertrand M, Montalescot G, Van Belle E.

Eur Heart J. 2012 Jan;33(2):191-202. doi: 10.1093/eurheartj/ehr176. Epub 2011 Jun 30.

13.

Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.

Hilleman DE, Bauman AL.

Pharmacotherapy. 2001 May;21(5):556-75. Review.

PMID:
11349745
14.

Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm.

Streitner F, Kuschyk J, Veltmann C, Ratay D, Schoene N, Streitner I, Brueckmann M, Schumacher B, Borggrefe M, Wolpert C.

Cytokine. 2009 Sep;47(3):166-72. doi: 10.1016/j.cyto.2009.06.003. Epub 2009 Jul 14.

PMID:
19604708
15.

Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.

Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, Tofler GH, Muller JE, Albert CM; TOVA Investigators.

Circulation. 2004 Mar 23;109(11):1386-91. Epub 2004 Mar 1.

16.

High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure.

Lamblin N, Mouquet F, Hennache B, Dagorn J, Susen S, Bauters C, de Groote P.

Eur Heart J. 2005 Nov;26(21):2245-50. Epub 2005 Sep 23.

17.

Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients.

Brenyo A, Rao M, Koneru S, Hallinan W, Shah S, Massey HT, Chen L, Polonsky B, McNitt S, Huang DT, Goldenberg I, Aktas M.

J Cardiovasc Electrophysiol. 2012 May;23(5):515-20. doi: 10.1111/j.1540-8167.2011.02223.x. Epub 2011 Nov 14.

PMID:
22081967
18.

Differences in outcomes between patients treated with single- versus dual-chamber implantable cardioverter defibrillators: a substudy of the Multicenter Automatic Defibrillator Implantation Trial II.

Berenbom LD, Weiford BC, Vacek JL, Emert MP, Hall WJ, Andrews ML, McNitt S, Zareba W, Moss AJ.

Ann Noninvasive Electrocardiol. 2005 Oct;10(4):429-35.

PMID:
16255753
19.

Ventricular tachycardia and sudden cardiac death.

Reddy PC, Tandon N, Stafford PR.

J La State Med Soc. 1999 May;151(5):281-7. Review.

PMID:
10363484
20.

Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.

Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.

J Cardiovasc Electrophysiol. 2012 Mar;23(3):296-301. doi: 10.1111/j.1540-8167.2011.02183.x. Epub 2011 Sep 28.

PMID:
21955243
Items per page

Supplemental Content

Write to the Help Desk